Senotherapeutic drugs: A new avenue for skincare?
dc.contributor.author | Lee, BP | |
dc.contributor.author | Harries, LW | |
dc.date.accessioned | 2022-05-13T09:46:35Z | |
dc.date.issued | 2021-11-29 | |
dc.date.updated | 2022-05-12T13:19:26Z | |
dc.description.abstract | SUMMARY: Skin aging is an outward manifestation of other cellular and molecular aging processes occurring elsewhere in the body. These processes are known collectively as the "hallmarks" of aging, which are a series of basic health maintenance mechanisms that fail over time. Cellular senescence is one of the most studied of the hallmarks of aging; senescent cells accumulate over time and are major drives of the aging process. Here, we discuss the impact of cellular senescence in the context of skin aging, and discuss the emerging landscape of interventions designed for their selective removal by targeted cell death (senolytics) or rejuvenation (senomorphics). We discuss the serotherapeutic strategies that are currently under investigation for systemic aging, which may bring eventual benefits for skin health. Next, we discuss a newly discovered hallmark of aging, dysregulated mRNA processing, which can be targeted for the senomorphic effect. Finally, we highlight a new modality for manipulation of disrupted mRNA processing, oligonucleotide therapeutics. The emerging field of senotherapeutics is set to revolutionize how we view and treat skin aging, and senotherapies are now poised to become a new class of skincare interventions. | en_GB |
dc.format.extent | 21S-26S | |
dc.format.medium | ||
dc.identifier.citation | Vol. 148(6S), pp. 21S-26S | en_GB |
dc.identifier.doi | https://doi.org/10.1097/PRS.0000000000008782 | |
dc.identifier.uri | http://hdl.handle.net/10871/129603 | |
dc.identifier | ORCID: 0000-0001-7791-8061 (Harries, Lorna W) | |
dc.identifier | ScopusID: 13805289700 (Harries, Lorna W) | |
dc.identifier | ResearcherID: D-2241-2014 | E-2369-2011 (Harries, Lorna W) | |
dc.language.iso | en | en_GB |
dc.publisher | Lippincott, Williams & Wilkins / American Society of Plastic Surgeons | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/34847094 | en_GB |
dc.rights.embargoreason | Under embargo until 29 November 2022 in compliance with publisher policy | en_GB |
dc.rights | © 2021 American Society of Plastic Surgeons. This version is made available under the CC-BY-NC 4.0 license: https://creativecommons.org/licenses/by-nc/4.0/ | en_GB |
dc.title | Senotherapeutic drugs: A new avenue for skincare? | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2022-05-13T09:46:35Z | |
dc.identifier.issn | 0032-1052 | |
exeter.place-of-publication | United States | |
dc.description | This is the author accepted manuscript. The final version is available from Lippincott, Williams & Wilkins via the DOI in this record | en_GB |
dc.identifier.eissn | 1529-4242 | |
dc.identifier.journal | Plastic and Reconstructive Surgery | en_GB |
dc.relation.ispartof | Plast Reconstr Surg, 148(6S) | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | en_GB |
dcterms.dateAccepted | 2021 | |
rioxxterms.version | AM | en_GB |
rioxxterms.licenseref.startdate | 2021-11-29 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2022-05-13T09:42:20Z | |
refterms.versionFCD | AM | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2021-11-29 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2021 American Society of Plastic Surgeons. This version is made available under the CC-BY-NC 4.0 license: https://creativecommons.org/licenses/by-nc/4.0/